Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Valoctocogene roxaparvovec (BMN 270) in Severe Hemophilia A
NCT03370913Phase 3Completed
- Sponsor
- BioMarin Pharmaceutical
- Start
- Dec 2017
- Primary completion
- Nov 2020
- Modality
- Gene Editing, Gene Silencing, AAV Vectors
- Countries
- 13
01
Overview
A Phase 3 trial of valoctocogene roxaparvovec in hemophilia A, sponsored by BioMarin Pharmaceutical. Started Dec 2017; status: completed.
02
Drugs
valoctocogene roxaparvovec
03
Conditions
hemophilia A
Beyond the preview
Go deeper on NCT03370913.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03370913.